FIELD: medical science.
SUBSTANCE: invention relates to medicine, specifically to neurology, and can be used in treating myasthenia gravis (MG). Use of the invention relates to the treatment of MG with zilucoplan. Treatment involves the daily subcutaneous administration of zilucoplan to a subject in a dose of zilucoplan 0.1 mg/kg of body weight to 0.6 mg/kg of body weight.
EFFECT: using the invention enables reducing manifestations of MG symptoms, improving the clinical response to the treatment, reducing the need for adjuvant therapy.
22 cl, 9 tbl, 18 dwg, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPLEMENT ACTIVITY MODULATORS | 2017 |
|
RU2778811C2 |
| MEMANTINE THERAPY FOR ALZHEIMER'S DISEASE OF LOW AND LOW TO MODERATE SEVERITY | 2005 |
|
RU2371173C2 |
| RAPID REDUCTION OF MOTOR FLUCTUATIONS ACCOMPANYING PARKINSON'S DISEASE | 2014 |
|
RU2698330C2 |
| PHARMACEUTICAL COMPOSITION FOR SAFE AND EFFECTIVE TREATMENT OF KNEE AND/OR HIP JOINT PAIN | 2019 |
|
RU2786232C2 |
| METHOD OF TREATING USING ANTI-CCL24 ANTIBODY | 2021 |
|
RU2832323C1 |
| COMPLEMENT ACTIVITY MODULATORS | 2016 |
|
RU2733720C2 |
| COMPLEMENT ACTIVITY MODULATORS | 2016 |
|
RU2769701C2 |
| TREATMENT OF PURULENT HIDRADENITIS | 2018 |
|
RU2772202C2 |
| TREATMENT OF ESSENTIAL TREMOR, USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUORETHOXY)PYRIDINE-2-YL)ETHYL)ACETAMIDE | 2019 |
|
RU2780318C1 |
| METHODS FOR COGNITIVE FUNCTION SUPPORT, TREATMENT OR IMPROVEMENT | 2013 |
|
RU2635522C2 |
